Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

被引：0
|
作者：
Aleš Linhart
Gabriela Dostálová
Kathy Nicholls
Michael L. West
Camilla Tøndel
Ana Jovanovic
Pilar Giraldo
Bojan Vujkovac
Tarekegn Geberhiwot
Einat Brill-Almon
Sari Alon
Raul Chertkoff
Rossana Rocco
Derralynn Hughes
机构：
[1] Charles University and General University Hospital in Prague,2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine
[2] Royal Melbourne Hospital and The University of Melbourne,Department of Nephrology
[3] Dalhousie University,Division of Nephrology, Department of Medicine
[4] University of Bergen,Department of Clinical Science
[5] Haukeland University Hospital,Nephrology and Rheumatology Unit, Department of Pediatrics
[6] Salford Royal,Department of Inherited Metabolic Disease
[7] Hospital de Dia Quiron,Centro de Investigación Biomédica en Red de Enfermedades Raras
[8] General Hospital Slovenj Gradec,Department of Internal Medicine
[9] University Hospitals Birmingham NHS Foundation Trust and University of Birmingham,Department of Diabetes, Endocrinology and Metabolism
[10] Protalix Biotherapeutics,Lysosomal Storage Disorders Unit
[11] Chiesi Farmaceutici S.p.A.,undefined
[12] Royal Free London NHS Foundation Trust and University College London,undefined
来源：
Orphanet Journal of Rare Diseases | / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] HGT-REP-059 treatment protocol: effect and tolerability of open-label agalsidase alfa in patients with Fabry disease
    Goker-Alpan, Ozlem
    Nedd, Khan
    Shankar, Suma
    Lien, Y. Howard
    Weinreb, Neal
    Wijatyk, Anna
    Chang, Peter
    Martin, Rick
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S48 - S48
  • [22] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
    Hughes, Derralynn
    Gonzalez, Derlis
    Maegawa, Gustavo
    Bernat, John
    Holida, Myrl
    Giraldo, Pilar
    Atta, Mohamed
    Chertkoff, Raul
    Alon, Sari
    Almon, Einat B.
    Rocco, Rossana
    Goker-Alpan, Ozlem
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S58 - S58
  • [23] ALFA PROTECT: A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAMOCTOCOG ALFA PEGOL IN PREVIOUSLY TREATED CHILDREN AGED 7<12 YEARS WITH SEVERE HEMOPHILIA A
    Ducore, Jonathan
    Enriquez, Monika Mass
    Tueckmantel, Claudia
    Simpson, Mindy
    Ahuja, Sanjay
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E31 - E31
  • [24] Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A
    Chowdary, Pratima
    Mullins, Eric S.
    Konkle, Barbara A.
    McGuinn, Catherine
    Park, Young Shil
    Stasyshyn, Oleksandra
    Zulfikar, Bulent
    Engl, Werner
    Tangada, Srilatha
    HAEMOPHILIA, 2020, 26 (04) : E168 - E178
  • [25] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
    Gonzalez, Derlis
    Maegawa, Gustavo
    Bernat, John
    Holida, Myrl
    Giraldo, Pilar
    Atta, Mohamed
    Chertkoff, Raul
    Alon, Sari
    Almon, Einat
    Rocco, Rossana
    Goker-Alpan, Ozlem
    GENETICS IN MEDICINE, 2022, 24 (03) : S91 - S91
  • [26] An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naive to enzyme replacement therapy
    Goker-Alpan, Ozlem
    Longo, Nicola
    McDonald, Marie
    Shankar, Suma P.
    Schiffmann, Raphael
    Chang, Peter
    Shen, Yinghua
    Pano, Arian
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1771 - 1781
  • [27] Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease
    Wraith, J. Edmond
    Tylki-Szymanska, Anna
    Guffon, Nathalie
    Lien, Y. Howard
    Tsimaratos, Michel
    Vellodi, Ashok
    German, Dominique P.
    JOURNAL OF PEDIATRICS, 2008, 152 (04): : 563 - 570
  • [28] Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey
    Giugliani, Roberto
    Hughes, Derralynn
    Nicholls, Kathy
    Niu, Dau-Ming
    Reisin, Ricardo C.
    Botha, Jaco
    Anagnostopoulou, Christina
    West, Michael L.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 49 - 50
  • [29] A phase 4, open label, multicenter prospective study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease
    Chen, Nan
    Ren, Hong
    Zhang, Wei
    Ouyang, Yan
    Xu, Hong
    Li, Bin
    Feng, Qiqi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [30] A phase 4, open label, multicenter prospective study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease
    Chen, Nan
    Ren, Hong
    Zhang, Wei
    Ouyang, Yan
    Xu, Hong
    Li, Bin
    Feng, Qiqi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1956 - I1958
12345